Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 January 2025 | Story Anthony Mthembu | Photo Supplied
Prof Solomon Werta
Prof Solomon Werta, UFS alumnus and Vice-President: Administration and Development at Dire Dawa University, continues to inspire as one of Ethiopia's youngest leaders in higher education.

Throughout the progression of his career, the UFS alumnus, Prof Solomon Werta – Vice-President: Administration and Development at the Dire Dawa University (DDU) – has been the ‘youngest’ to occupy positions of leadership in several instances. 

In fact, the DDU appointed Prof Werta as Vice-President: Research and Community Service in 2020, making him the youngest vice-president of any public university in Ethiopia. According to Prof Werta, when it comes to senior management roles in universities and government, the norm is that the positions are held by middle-aged, mature leaders. However, after a unanimous vote by senate members at the university, he assumed that role at the age of 31. “Holding such a senior position at that age makes me a role model not only for a generation of young people, but for those at the University of the Free State who may be following my career,” Prof Werta stated. 

What the role entailed 

As Vice-President: Research and Community Service, he was responsible for driving research, innovation, technology transfer, community engagement, and growth within the institution and the community at large. As such, some of his highlights within this role include establishing a university community radio station to serve both the university and the Dire Dawa community, establishing new university journals such as the Harla journal, and establishing a nationally accredited institutional review board, among others. 

He occupied this role until November 2023 when he was promoted to his current role as Vice-President: Administration and Development at the DDU. Prof Werta credits this most recent promotion to the dedication and hard work he put into his previous role, as well as the knowledge and experience he acquired during his time at the UFS. 

In recognition of his work as a researcher within the Department of Physics at the DDU, Prof Werta was also promoted to Associate Professor in Physics. As a result, he indicates that he can be regarded as the youngest associate professor of physics in Ethiopia. Therefore, he continues to contribute to his institution and beyond on these accounts. 

What the future holds 

Prof Werta indicated that he plans on continuing to make strides as his career progresses, particularly in his role as Vice-President: Administration and Development. “I’d like to focus on increasing the university’s internal revenue, particularly through urban farming and other businesses using our academics,” said Prof Werta. In addition, he would also like to work on changing the university’s internal business practices, particularly the automation and digitalisation of the university system and the implementation of a contemporary university property management system, among others. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept